Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry

被引:145
|
作者
Holzer, Ralf
de Giovanni, Jo
Walsh, Kevin P.
Tometzki, Andrew
Goh, T. H.
Hakim, Fakhri
Zabal, Carlos
de Lezo, Jose Suarez
Cao, Qi-Ling
Hijazi, Ziyad M.
机构
[1] Univ Chicago, Corner Childrens Hosp, Pritzker Sch Med, Dept Pediat,Sect Cardiol, Chicago, IL 60637 USA
[2] Childrens Hosp, Birmingham, W Midlands, England
[3] Our Ladys Hosp Sick Children, Dublin, Ireland
[4] Childrens Hosp, Bristol, Avon, England
[5] Royal Childrens Hosp, Melbourne, Vic, Australia
[6] Queen Alia Heart Inst, Amman, Jordan
[7] Inst Nacl Cardiol Ignacio Chavez, Mexico City, DF, Mexico
[8] Hosp Reina Sofia, Cordoba, Spain
关键词
perimembranous ventricular septal defect; catheterization; interventional;
D O I
10.1002/ccd.20659
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To report the immediate and midterm results of transcatheter closure of perimembranous ventricular septal defect (PmVSD) using the Amplatzer membranous VSD occluder (AMVSD). Methods: Between April 2002 and August 2004, 100 patients underwent an attempt of percutaneous device closure of PmVSD using the AMVSD in 24 international centers. The median age was 9.0 years (0.7-58 years) and the median weight was 27.5 kg (7-121 kg). Results: A device was successfully deployed in 93/100 (93%) patients. Reasons for procedural failure were an increased gradient across the left ventricle outflow tract in one patient, aortic regurgitation in 2 patients, and inability to securely position the device in 4 patients. The median VSD size by TEE was 7.0 mm (1.5-13 mm), median device size 10 mm (4-16 mm) and median fluoroscopy time 22.1 min (8.9-96.0 min). Weight below 10 kg (P = 0.0392), inlet extension of the VSD (P = 0.0139) and aortic cusp prolapse into the VSD (P = 0.0084) were significantly associated with a lower procedural success. Patients have been followed up for a median of 182 days (1-763 days). There were no procedure-related deaths. Complications were encountered in 29/100 (29%) patients, including rhythm or conduction anomalies in 13 patients (two with complete heart block requiring permanent pacemaker implantation), new or increased aortic (9 patients) or tricuspid (9 patients) regurgitation, most of which were classified as trivial or mild. Patients with a weight below 10 kg had a significantly higher incidence of adverse events than patients with a weight above 10 kg (58.3% versus 25.0%, P = 0.0285). Immediately after device release complete closure of the defect was present in 54/93 (58.1%) patients, increasing to 46/55 (83.6%) patients at 6-months follow-up (P = 0.0012). Left ventricle end-diastolic diameter decreased from a median of 44 mm prior to device closure to a median of 39 mm at 6-months postprocedure (P = 0.0015). Conclusion: Closure of PmVSDs using the AMVSD occluder is safe and effective. However, longer follow-up period is warranted prior to the wide spread use of this device. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:620 / 628
页数:9
相关论文
共 50 条
  • [31] Transcatheter closure of congenital perimembranous ventricular septal defect using the Amplatzer duct occluder 2
    Zhao, Li-Jian
    Han, Bo
    Zhang, Jian-Jun
    Yi, Ying-Chun
    Jiang, Dian-Dong
    Lyu, Jian-Li
    CARDIOLOGY IN THE YOUNG, 2018, 28 (03) : 447 - 453
  • [32] Transcatheter closure of perimembranous and intracristal ventricular septal defects with the shsma occluder
    Zhou, Daxin
    Pan, Wenzhi
    Guan, Lihua
    Ge, Junbo
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2012, 79 (04) : 666 - 674
  • [33] Transcatheter Closure of Perimembranous Ventricular Septal Defects With Amplatzer Duct Occluders
    Lin, Ming-Tai
    Chen, Chun-An
    Hsu, Jui-Yu
    Lin, Hsin-Chia
    Chiu, Shuenn-Nan
    Lin, Shu-Man
    Chang, Ya-Mei
    Lu, Chun-Wei
    Wu, Mei-Hwan
    Wang, Jou-Kou
    JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (21) : 2227 - 2228
  • [34] Transcatheter closure of small-large muscular ventricular septal defects using the new amplatzer VSD occluder: Initial clinical results
    Madani, A
    Hakim, F
    Hirai, A
    AbuAta, I
    Goussous, YM
    Hijazi, ZM
    CIRCULATION, 1999, 100 (18) : 321 - 321
  • [35] Outcome of transcatheter closure of muscular ventricular septal defects using the amplatzer ventricular septal defect occluder
    Thanopoulos, BD
    Rigby, ML
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 473A - 473A
  • [36] Efficacy and Safety of Using Amplatzer Ductal Occluder for Transcatheter Closure of Perimembranous Ventricular Septal Defect in Pediatrics
    Ghaderian, Mehdi
    Merajie, Mahmood
    Mortezaeian, Hodjjat
    Aarabi, Moghadam
    Mohammad, Yoosef
    Mohammadi, Akbar Shah
    IRANIAN JOURNAL OF PEDIATRICS, 2015, 25 (02)
  • [37] Transcatheter Closure of Perimembranous Ventricular Septal Defect With the Amplatzer® Membranous VSD Occluder 2: Initial World Experience and One-Year Follow-Up
    Tzikas, Apostolos
    Ibrahim, Reda
    Velasco-Sanchez, Daniel
    Freixa, Xavier
    Alburquenque, Marcela
    Khairy, Paul
    Bass, John L.
    Ramirez, Juan
    Aguirre, Daniel
    Miro, Joaquim
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2014, 83 (04) : 571 - 580
  • [38] Outcome of transcatheter closure of muscular ventricular septal defects with the Amplatzer ventricular septal defect occluder
    Thanopoulos, BD
    Rigby, ML
    HEART, 2005, 91 (04) : 513 - 516
  • [39] Transcatheter Membranous Ventricular Septal Defect Closure Through a Mechanical Aortic Prosthesis Using the Amplatzer Membranous Ventricular Septal Defect Occluder
    Noble, Stephane
    Ibrahim, Reda
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2009, 73 (02) : 167 - 172
  • [40] Transcatheter closure of post-infarction ventricular septal defects with the Amplatzer septal occluder
    Demkow, M
    Ruzyllo, W
    Chmielak, Z
    Konka, M
    Dzielinska, Z
    Wilczynski, J
    EUROPEAN HEART JOURNAL, 2001, 22 : 63 - 63